##gff-version 3
##sequence-region Q01726 1 317
Q01726	UniProtKB	Chain	1	317	.	.	.	ID=PRO_0000069818;Note=Melanocyte-stimulating hormone receptor	
Q01726	UniProtKB	Topological domain	1	37	.	.	.	Note=Extracellular;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Transmembrane	38	63	.	.	.	Note=Helical%3B Name%3D1;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Topological domain	64	72	.	.	.	Note=Cytoplasmic;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Transmembrane	73	93	.	.	.	Note=Helical%3B Name%3D2;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Topological domain	94	118	.	.	.	Note=Extracellular;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Transmembrane	119	140	.	.	.	Note=Helical%3B Name%3D3;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Topological domain	141	163	.	.	.	Note=Cytoplasmic;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Transmembrane	164	183	.	.	.	Note=Helical%3B Name%3D4;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Topological domain	184	191	.	.	.	Note=Extracellular;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Transmembrane	192	211	.	.	.	Note=Helical%3B Name%3D5;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Topological domain	212	240	.	.	.	Note=Cytoplasmic;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Transmembrane	241	266	.	.	.	Note=Helical%3B Name%3D6;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Topological domain	267	279	.	.	.	Note=Extracellular;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Transmembrane	280	300	.	.	.	Note=Helical%3B Name%3D7;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Topological domain	301	317	.	.	.	Note=Cytoplasmic;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Lipidation	315	315	.	.	.	Note=S-palmitoyl cysteine;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Glycosylation	29	29	.	.	.	Note=N-linked (GlcNAc...) asparagine;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q01726	UniProtKB	Natural variant	38	38	.	.	.	ID=VAR_059018;Note=In CMM5%3B moderate decrease in coupling to the cAMP pathway%3B reduced cell surface expression as a consequence of retention in the endoplasmic reticulum. V->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19338054;Dbxref=dbSNP:rs200050206,PMID:19338054	
Q01726	UniProtKB	Natural variant	40	40	.	.	.	ID=VAR_013611;Note=Associated with fair hair and light skin%3B partial loss-of-function. I->T;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11707265;Dbxref=dbSNP:rs748138541,PMID:11707265	
Q01726	UniProtKB	Natural variant	41	41	.	.	.	ID=VAR_059019;Note=In CMM5%3B complete absence of functional coupling to the cAMP pathway%3B reduced cell surface expression as a consequence of retention in the endoplasmic reticulum. S->F;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:17434924,ECO:0000269|PubMed:19338054;Dbxref=PMID:17434924,PMID:19338054	
Q01726	UniProtKB	Natural variant	51	51	.	.	.	ID=VAR_059020;Note=In CMM5%3B moderate decrease in coupling to the cAMP pathway%3B reduced cell surface expression as a consequence of retention in the endoplasmic reticulum. V->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19338054;Dbxref=dbSNP:rs766080391,PMID:19338054	
Q01726	UniProtKB	Natural variant	60	60	.	.	.	ID=VAR_013612;Note=Associated with a risk for developing melanoma%3B unable to stimulate cAMP production as strongly as the wild type receptor in response to alpha-melanocyte-stimulating hormone stimulation. V->L;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10403794,ECO:0000269|PubMed:17434924,ECO:0000269|PubMed:18987736,ECO:0000269|PubMed:9302268,ECO:0000269|Ref.12;Dbxref=dbSNP:rs1805005,PMID:10403794,PMID:17434924,PMID:18987736,PMID:9302268	
Q01726	UniProtKB	Natural variant	67	67	.	.	.	ID=VAR_009522;Note=Shows a moderate and not significant decrease of cAMP production to NDP-MSH stimulation%3B shows a decreased responses to low concentrations of NDP-MSH stimulation. R->Q;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10101176,ECO:0000269|PubMed:16463023;Dbxref=dbSNP:rs34090186,PMID:10101176,PMID:16463023	
Q01726	UniProtKB	Natural variant	84	84	.	.	.	ID=VAR_003507;Note=May be associated with a risk for developing melanoma%3B reduced expression at the cell surface. D->E;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10101176,ECO:0000269|PubMed:15972726,ECO:0000269|PubMed:8894704,ECO:0000269|PubMed:8990005;Dbxref=dbSNP:rs1805006,PMID:10101176,PMID:15972726,PMID:8894704,PMID:8990005	
Q01726	UniProtKB	Natural variant	89	89	.	.	.	ID=VAR_042654;Note=G->R;Dbxref=dbSNP:rs34540312	
Q01726	UniProtKB	Natural variant	92	92	.	.	.	ID=VAR_003508;Note=Associated with a risk for developing melanoma%3B predominantly found in type I skin%3B shows a moderate and not significant decreased of cAMP production to NDP-MSH stimulation. V->M;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10101176,ECO:0000269|PubMed:16463023,ECO:0000269|PubMed:17434924,ECO:0000269|PubMed:18987736,ECO:0000269|PubMed:8990005,ECO:0000269|PubMed:9302268,ECO:0000269|Ref.12;Dbxref=dbSNP:rs2228479,PMID:10101176,PMID:16463023,PMID:17434924,PMID:18987736,PMID:8990005,PMID:9302268	
Q01726	UniProtKB	Natural variant	93	93	.	.	.	ID=VAR_059021;Note=Loss-of-function mutation abolishing agonist binding. L->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12473109;Dbxref=PMID:12473109	
Q01726	UniProtKB	Natural variant	95	95	.	.	.	ID=VAR_042655;Note=T->M;Dbxref=dbSNP:rs34158934	
Q01726	UniProtKB	Natural variant	104	104	.	.	.	ID=VAR_042656;Note=G->S;Dbxref=dbSNP:rs2229617	
Q01726	UniProtKB	Natural variant	120	120	.	.	.	ID=VAR_042657;Note=Shows a moderate and not significant decrease of cAMP production to NDP-MSH stimulation%3B shows decreased responses to low concentrations of NDP-MSH stimulation. I->T;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16463023;Dbxref=dbSNP:rs33932559,PMID:16463023	
Q01726	UniProtKB	Natural variant	122	122	.	.	.	ID=VAR_013613;Note=Associated with fair hair and light skin%3B partial loss-of-function. V->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11707265;Dbxref=dbSNP:rs201192930,PMID:11707265	
Q01726	UniProtKB	Natural variant	128	128	.	.	.	ID=VAR_059022;Note=In CMM5%3B complete absence of functional coupling to the cAMP pathway%3B trafficked to the cell surface but unable to bind agonist efficiently. M->T;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:17434924,ECO:0000269|PubMed:19338054;Dbxref=dbSNP:rs374235260,PMID:17434924,PMID:19338054	
Q01726	UniProtKB	Natural variant	142	142	.	.	.	ID=VAR_059023;Note=R->H;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10403794,ECO:0000269|PubMed:12473109;Dbxref=dbSNP:rs11547464,PMID:10403794,PMID:12473109	
Q01726	UniProtKB	Natural variant	147	147	.	.	.	ID=VAR_042658;Note=Associated with UV induced susceptibility to skin damage%3B unresponsive to NDP-MSH stimulation. Missing;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16463023;Dbxref=PMID:16463023	
Q01726	UniProtKB	Natural variant	151	151	.	.	.	ID=VAR_008522;Note=Associated with red hair and light skin of type I%3B binds to alpha-MSH but cannot be stimulated to produce cAMP%3B reduced expression at the cell surface. R->C;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10101176,ECO:0000269|PubMed:10403794,ECO:0000269|PubMed:12473109,ECO:0000269|PubMed:15972726,ECO:0000269|PubMed:16463023,ECO:0000269|PubMed:17952075,ECO:0000269|PubMed:9302268,ECO:0000269|PubMed:9571181,ECO:0000269|Ref.12;Dbxref=dbSNP:rs1805007,PMID:10101176,PMID:10403794,PMID:12473109,PMID:15972726,PMID:16463023,PMID:17952075,PMID:9302268,PMID:9571181	
Q01726	UniProtKB	Natural variant	155	155	.	.	.	ID=VAR_013614;Note=Associated with a risk for developing melanoma%3B reduced expression at the cell surface. I->T;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15489334,ECO:0000269|PubMed:15972726,ECO:0000269|PubMed:17434924,ECO:0000269|Ref.12;Dbxref=dbSNP:rs1110400,PMID:15489334,PMID:15972726,PMID:17434924	
Q01726	UniProtKB	Natural variant	156	156	.	.	.	ID=VAR_013615;Note=V->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|Ref.12;Dbxref=dbSNP:rs3212365	
Q01726	UniProtKB	Natural variant	157	157	.	.	.	ID=VAR_042659;Note=Associated with UV induced susceptibility to skin damage%3B shows a dramatically decreased cAMP production to NDP-MSH stimulation. T->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16463023;Dbxref=dbSNP:rs104894524,PMID:16463023	
Q01726	UniProtKB	Natural variant	159	159	.	.	.	ID=VAR_042660;Note=Associated with UV induced susceptibility to skin damage%3B shows a strong decreased cAMP production to NDP-MSH stimulation. P->T;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16463023;Dbxref=dbSNP:rs104894523,PMID:16463023	
Q01726	UniProtKB	Natural variant	160	160	.	.	.	ID=VAR_008523;Note=Associated with a risk for developing melanoma%3B unable to stimulate cAMP production as strongly as the wild type receptor in response to alpha-melanocyte-stimulating hormone stimulation%3B reduced expression at the cell surface. R->W;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10403794,ECO:0000269|PubMed:15972726,ECO:0000269|PubMed:17434924,ECO:0000269|PubMed:9302268,ECO:0000269|PubMed:9665397,ECO:0000269|Ref.12;Dbxref=dbSNP:rs1805008,PMID:10403794,PMID:15972726,PMID:17434924,PMID:9302268,PMID:9665397	
Q01726	UniProtKB	Natural variant	162	162	.	.	.	ID=VAR_013632;Note=R->P;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11442765;Dbxref=PMID:11442765	
Q01726	UniProtKB	Natural variant	163	163	.	.	.	ID=VAR_009523;Note=Associated with a risk for developing melanoma%3B shows a moderate and not significant decrease of cAMP production to NDP-MSH stimulation%3B shows a not significant decrease in cAMP production at any concentrations of NDP-MSH stimulation. R->Q;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10101176,ECO:0000269|PubMed:16463023,ECO:0000269|PubMed:17434924,ECO:0000269|Ref.12;Dbxref=dbSNP:rs885479,PMID:10101176,PMID:16463023,PMID:17434924	
Q01726	UniProtKB	Natural variant	166	166	.	.	.	ID=VAR_042661;Note=Shows a moderate and not significant decrease of cAMP production to NDP-MSH stimulation%3B shows a not significant decrease in cAMP production at any concentrations of NDP-MSH stimulation. A->G;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16463023;Dbxref=dbSNP:rs35040147,PMID:16463023	
Q01726	UniProtKB	Natural variant	171	171	.	.	.	ID=VAR_042662;Note=A->S;Dbxref=dbSNP:rs35784916	
Q01726	UniProtKB	Natural variant	196	196	.	.	.	ID=VAR_013616;Note=F->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|Ref.12;Dbxref=dbSNP:rs3212366	
Q01726	UniProtKB	Natural variant	281	281	.	.	.	ID=VAR_059024;Note=Functionally silent polymorphism%3B does not affect receptor surface expression%2C agonist binding and agonist-induced signaling. N->S;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:17434924,ECO:0000269|PubMed:19338054;Dbxref=dbSNP:rs141177570,PMID:17434924,PMID:19338054	
Q01726	UniProtKB	Natural variant	289	289	.	.	.	ID=VAR_059025;Note=In CMM5%3B complete absence of functional coupling to the cAMP pathway%3B trafficked to the cell surface but unable to bind agonist efficiently. C->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19338054;Dbxref=dbSNP:rs369542041,PMID:19338054	
Q01726	UniProtKB	Natural variant	294	294	.	.	.	ID=VAR_008524;Note=Associated with a risk for developing melanoma%3B unable to stimulate cAMP production as strongly as the wild type receptor in response to alpha-melanocyte-stimulating hormone stimulation. D->H;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10403794,ECO:0000269|PubMed:17434924,ECO:0000269|PubMed:7581459,ECO:0000269|PubMed:9302268;Dbxref=dbSNP:rs1805009,PMID:10403794,PMID:17434924,PMID:7581459,PMID:9302268	
Q01726	UniProtKB	Mutagenesis	65	65	.	.	.	Note=Only minor effect on internalization rate and protein half-life%3B when associated with R-226%3B R-238 and R-310. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19737927;Dbxref=PMID:19737927	
Q01726	UniProtKB	Mutagenesis	226	226	.	.	.	Note=Only minor effect on internalization rate and protein half-life%3B when associated with R-65%3B R-238 and R-310. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19737927;Dbxref=PMID:19737927	
Q01726	UniProtKB	Mutagenesis	238	238	.	.	.	Note=Only minor effect on internalization rate and protein half-life%3B when associated with R-65%3B R-226 and R-310. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19737927;Dbxref=PMID:19737927	
Q01726	UniProtKB	Mutagenesis	310	310	.	.	.	Note=Only minor effect on internalization rate and protein half-life%3B when associated with R-65%3B R-226 and R-238. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19737927;Dbxref=PMID:19737927	
Q01726	UniProtKB	Sequence conflict	90	90	.	.	.	Note=S->T;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q01726	UniProtKB	Sequence conflict	90	90	.	.	.	Note=S->T;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q01726	UniProtKB	Sequence conflict	164	164	.	.	.	Note=A->R;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q01726	UniProtKB	Sequence conflict	222	222	.	.	.	Note=A->T;Ontology_term=ECO:0000305;evidence=ECO:0000305	
